A recent study indicates that patients who discontinue popular GLP-1 drugs like semaglutide or tirzepatide tend to recover shed pounds much more quickly than those who stop conventional lifestyle plans.
Published data in a leading medical journal demonstrates that while obese individuals frequently drop substantial amounts of their body weight while on the medication, the weight is regained at an average rate of nearly a kilo each month once they quit.
"Individuals purchasing these treatments must be aware of the potential of fast weight regain when the treatment is stopped," stated researcher Dr. Susan Jebb.
That rate of regain implies a reversion to starting weight in about one and a half years.
Comparing Therapies
The study, which examined 37 of studies involving over 9,000 of patients, contrasted the results of the injectable medications with older methods.
Scientists note that people who lose weight through lifestyle changes alone usually see a less rapid creep back—approximately 100 grams monthly—post-intervention.
Explaining the Rapid Rebound
Experts propose the mode of action of the jabs accounts for the amplified rebound.
The injections imitate a body's own chemical called glucagon-like peptide-1, which controls hunger.
"Artificially providing GLP-1 levels several times higher than the body's typical production might result in the system to produce less of its own natural GLP-1, and may also reduce responsiveness to its effects," explained Dr. Adam Collins, a nutrition specialist.
"Stopping of this medication leads to hunger is uncontrolled, making binge eating much more probable."
A Lifelong Disease?
Medical guidelines suggest the injections for individuals with obesity-related health risks, accompanied by recommended diet and exercise modifications.
A number of clinicians contend that, considering the high risk of relapse, the therapy should be considered life-long.
This opinion is echoed by drug manufacturers, who note that the findings "emphasize the long-term nature of obesity," akin to managing conditions like hypertension.
Patient Testimonies
Users who have discontinued the medication describe a powerful return of cravings.
"It felt as if something flipping and you're instantly extremely hungry," described an individual.
This challenge is exacerbated if patients have not adopted sustainable dietary or behavioural changes during treatment.
Growing Use
Survey data indicate that millions of adults in the UK have used these injections in the past year, with demand being substantial.
- Adoption is greater among females compared to males.
- The middle-aged demographic shows the highest usage rates.
- A large proportion obtain the medications through private prescriptions rather than public health services.
In conclusion, clinicians stress that while GLP-1 drugs are powerful tools for shedding pounds, they are not a standalone cure and maintained weight loss relies on integrated behavioural management.
